Esperion Therapeutics (NASDAQ: ESPR)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Esperion Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Esperion Therapeutics Company Info
Esperion Therapeutics, Inc. is a pharmaceutical company. It engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.
News & Analysis
Shareholders were displeased with the company's latest financial move.
It was all about the earnings.
The company gave a sneak peek into its fourth-quarter financial results.
Sales of these recently launched products could make a big difference for the companies behind them.
These companies scored recent drug approvals. It's worth looking into their stocks to see if they're a buy now.
Millions of patients who don't respond well enough to statins now have another affordable alternative.
From a niche contraceptive to the world's top cancer treatment, the FDA has a number of interesting drugs it's reviewing this month.
The committee vote puts bempedoic acid on the path for likely approval by the European Medicines Agency.
Valuation
Earnings Transcripts
ESPR earnings call for the period ending June 30, 2022.
ESPR earnings call for the period ending March 31, 2022.
ESPR earnings call for the period ending December 31, 2021.
ESPR earnings call for the period ending September 30, 2021.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.